Hello Atlas Venture Partner

Welcome to Atlas Ventures Partner Portal. Here you will have access to all the newest information and resources catering to your specific needs and interests. Sign in below for instant access.

Sign In Here

Atlas Venture logo

Collaborative Learning

Charles River Presents: The Innovator Series

Learn from entrepreneurs like you who took their discoveries from idea to reality…

 

Learn More about the innovator series...

Resource Links

Need more information on a specific therapeutic area or technology? Check out these resources…

Oncology

 •   Charles River Oncology
 •   Oncology Analysis Methods & Endpoints
 •   Oncology Models
 •   Oncology Assays
 •   Oncology & Immuno-Oncology Studies

Neuroscience

 •   Neuroscience Microsite
 •   Neuroscience Methods & Endpoints
 •   Neuroscience Studies

Platforms and Technologies

 •   Hit Finding eGuide for Hit Identification
 •   Antibody Library Screening for Antibody Discovery
 •   Screening and Profiling Assays

Immunology/Inflammation

 •   Immunology Microsite
 •   Inflammation & Autoimmune Disease Studies
 •   In Vitro Immunology

Other

 •   Cardiovascular/Metabolic Disease Studies
 •   Musculoskeletal Disease Studies
 •   Ocular Disease Studies

Charles River drug discovery uses large compound libraries and high throughput screening (HTS) technology for the identification of hit compounds and assay development.

High-Throughput Screening

Utilizing vast compound libraries, chemists use high-throughput screening to rapidly identify promising compounds for neuroscience target validation and identification.


Antisense Oligonucleotide (ASO) Screening

ASO screens can be designed to evaluate a variety of proven mechanism of action approaches for antisense oligonucleotide therapy. To date, we’ve developed ASO screening assays primarily for rare neurodegenerative disorders.

Binding of antisense oligonucleotide to RNA for use in Antisense oligonucleotide therapy.

Medicinal chemistry (medchem) and pharmaceutical chemistry services are critical to drive your drug discovery project and Charles River chemists have the experience and knowledge to bring compounds of interest to clinic faster.

Medicinal Chemistry

Modern medicinal chemistry is highly multidisciplinary, driving CNS drug discovery innovation from novel synthesis and delivery to screening. Small molecule and large molecule CNS targets range from GPCRs to kinase inhibitors and have proven useful for studying diseases of neurodegeneration such as Parkinson’s disease and Huntington’s disease.


High Content Imaging

In CNS research, we use high content imaging to characterize stem cell-derived neuronal lineages and a host of validated assays like apoptosis, autophagy, protein aggregation, cell or mitochondrial motility and migration, epigenetic modifications, maker expression, protein acetylation and phosphorylation, receptor internalization and degradation, sub-cellular localization and translocation of transcription factors.

High Content Imaging using Multiplex Cell Painting. HeLa cells stained with six fluorescent dyes after exposure to Colchicine therapy.

Image of stem cells such as functional engineered human cells iPS cells are used to develop custom cell-based assays for drug screening.

Human iPSCs

Generating induced pluripotent stem cells (IPSCs) for neurological disease-relevant assays, coupled with specific differentiation protocols for production of neurons and/or astrocytes, improves translation to in vivo models.


CRISPR Gene Editing

CRISPR Cas9 gene editing has transformed drug discovery and development. It has been used successfully for editing the Huntington CAG repeat in human iPSCs and for high-content screening of disease-relevant in vitro assays for ALS.

illustration of genetic engineering and gene manipulation used in CRISPR Cas 9 technology

Charles River proteomics services include sample extraction, protein fractionation, peptide fractionation, mass spectrometry.

Proteomics

Neurological disease research and drug discovery uses proteomics to search for disease or pharmacological signatures. This allows us to understand biological mechanisms and identify specific proteins and their modifications, e.g., ubiquitination or phosphorylation in Parkinson’s disease and Huntington’s disease models.


Ion Channel Profiling

Our ion channel assays guide your early screening investigations and selectivity profiling with 120 targets organized in functionally-validated disease areas. CNS-focused Channel Panels™ include pain, psychiatric disorders, neurodegeneration, and seizure disorders.

DI-000119